The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
The study has shown that patients on Zejula had longer progression-free survival than those on placebo regardless of their BRCA1/2 mutation or HRD status.
The differing effects of BRCA mutations by tumor lineage could have ramifications for treatments targeting the DNA repair process, the research team said.
